Bioequivalence Study of Naproxen 500 mg/Esomeprazole 20 mg Modified-Release Tablets Versus Vimovo® in Healthy Subjects

The primary objective of this study is to evaluate the **bioequivalence** of Naproxen 500 mg/Esomeprazole 20 mg modified-release tablets (Antibiotice S.A.) compared to Vimovo® 500 mg/20 mg film-coated tablets (Grunenthal GmbH) in a fed state. This is clinically relevant as establishing bioequivalence ensures that the generic formulation provides the same therapeutic effect and safety profile as the branded medication, which is crucial for maintaining consistent patient outcomes. The study is conducted in healthy subjects to assess the pharmacokinetic parameters without the influence of disease-related variables.

The clinical trial involves **healthy subjects** with an age range of 18 to 65 years, encompassing both male and female participants. The sponsor did not provide information regarding the total number of participants. The trial population was selected to include individuals who are not part of a vulnerable population. Participants are expected to maintain their usual lifestyle, including diet and physical activity, without any specific restrictions or requirements. The study does not focus on any particular lifestyle considerations or habits. Key inclusion or exclusion criteria were not specified by the sponsor.

The clinical trial is designed as a **randomized**, **double-blind**, **controlled** study to evaluate the **bioequivalence** of Naproxen 500 mg/Esomeprazole 20 mg modified-release tablets compared to Vimovo® 500 mg/20 mg film-coated tablets. The study will involve **healthy subjects** and is categorized as a Phase 2 trial. The trial is expected to commence recruitment on January 1, 2024, and conclude by July 1, 2024. Participants will be involved in the study for the duration of the trial, with specific visits scheduled to ensure comprehensive data collection and monitoring.

The sequence of study visits includes an initial **screening** visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized and undergo a series of study visits, which may include dosing visits and follow-up assessments to monitor safety and efficacy. The end-of-study visit will be conducted to gather final data and ensure participant well-being. The expected length of participant involvement is aligned with the overall trial duration, from recruitment to the end-of-study visit.

Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is structured to maintain scientific rigor and ensure the safety and rights of participants throughout the study period.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. The absence of these details suggests that the focus is primarily on the experimental medication, although further clarification would be necessary to confirm this aspect of the trial design.

Due to the lack of specific information, it is not possible to provide additional relevant details about drug administration, dosing schedules, or participant compliance monitoring. The trial documentation does not include any data on the product's authorization status, pharmaceutical form, or the origin of the active substances involved. Consequently, the description remains limited to the general framework of the clinical trial without specific insights into the treatment regimen.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on January 1, 2024, with an estimated completion date of July 1, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not specified. The trial will adhere to standard clinical trial protocols to ensure the reliability and validity of the efficacy assessments. The study will be conducted in accordance with regulatory guidelines and ethical standards to ensure the integrity of the data collected.